Mycovia tackling chronic infections with antifungal pipeline

Mycovia plans to bring a new generation of antifungals against CYP51 to market for difficult-to-treat indications, starting with chronic vaginal and nail infections.

The company's lead product VT-1161 otesaconazole is in Phase III testing for recurrent vulvovaginal candidiasis (rVVC), a chronic yeast infection that affects about 138 million women worldwide every year. ...